Braden M. Leonard

Insider Reports History

Reporting-owner location: Zionsville, IN
Latest reporting-owner signature: Braden M Leonard
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Braden M. Leonard

Form 4 holding 10%+ Owner

Gemini Therapeutics, Inc. /DE

Security class: Common Stock
Shares / value: 5,000,000
Estimated value: $338,250,000
Report date: 26 Oct 2022
Price: $67.65
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Aclaris Therapeutics, Inc.

Security class: Common Stock
Shares / value: 13,950,000
Estimated value: $63,193,500
Report date: 23 Apr 2026
Price: $4.53
Ownership: Holdings of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

IMARA Inc.

Security class: Common Stock
Shares / value: 1,767,774
Estimated value: $26,755,259
Report date: 04 Jan 2023
Price: $15.14
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Aclaris Therapeutics, Inc.

Security class: Common Stock
Shares / value: 14,250,000
Estimated value: $17,731,275
Report date: 05 Aug 2024
Price: $1.24
Ownership: Holding of BML Investment Partners, L.P

Form 4 holding 10%+ Owner

Gemini Therapeutics, Inc. /DE

Security class: Common Stock
Shares / value: 247,500
Estimated value: $16,743,375
Report date: 26 Oct 2022
Price: $67.65
Ownership: Direct

Form 4 holding 10%+ Owner

Cyteir Therapeutics, Inc.

Security class: Common Stock, par value $0.001 per share
Shares / value: 3,654,053
Estimated value: $10,779,456
Report date: 20 Mar 2024
Price: $2.95
Ownership: Holding of BML Investment Partners, L.P

Form 4 holding 10%+ Owner

Outset Medical, Inc.

Security class: Common Stock
Shares / value: 2,519,701
Estimated value: $9,675,651
Report date: 15 May 2026
Price: $3.84
Ownership: Holdings of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Adverum Biotechnologies, Inc.

Security class: Common Stock
Shares / value: 1,958,080
Estimated value: $8,213,558
Report date: 04 Dec 2025
Price: $4.19
Ownership: Holdings of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Satsuma Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 6,440,000
Estimated value: $5,860,400
Report date: 21 Nov 2022
Price: $0.9100
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

IMARA Inc.

Security class: Common Stock
Shares / value: 230,000
Estimated value: $3,481,050
Report date: 03 Jan 2023
Price: $15.14
Ownership: Direct

Form 4 holding 10%+ Owner

AN2 Therapeutics, Inc.

Security class: Common Stock
Shares / value: 3,017,432
Estimated value: $3,289,000
Report date: 28 May 2025
Price: $1.09
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Metacrine, Inc.

Security class: Common Stock
Shares / value: 6,160,570
Estimated value: $2,895,468
Report date: 21 Dec 2022
Price: $0.4700
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Cyteir Therapeutics, Inc.

Security class: Common Stock, par value $0.001 per share
Shares / value: 335,000
Estimated value: $988,250
Report date: 20 Mar 2024
Price: $2.95
Ownership: Direct

Form 4 holding 10%+ Owner

RETRACTABLE TECHNOLOGIES INC

Security class: Common Stock
Shares / value: 688,575
Estimated value: $846,947
Report date: 29 Dec 2022
Price: $1.23
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Adverum Biotechnologies, Inc.

Security class: Common Stock
Shares / value: 191,800
Estimated value: $817,068
Report date: 04 Dec 2025
Price: $4.26
Ownership: Direct

Form 4 holding Former 10% owner of AVROBIO

Tectonic Therapeutic, Inc.

Security class: Common Stock
Shares / value: 400,355
Estimated value: $520,462
Report date: 20 Jun 2024
Price: $1.30
Ownership: Holding of BML Investment Partners, L.P,

Form 4 holding Former 10% owner of RPHM

Reneo Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 345,739
Estimated value: $517,364
Report date: 07 Oct 2024
Price: $1.50
Ownership: Holdings of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

RETRACTABLE TECHNOLOGIES INC

Security class: Common Stock
Shares / value: 387,500
Estimated value: $476,625
Report date: 29 Dec 2022
Price: $1.23
Ownership: Direct

Form 4 holding 10%+ Owner

Outset Medical, Inc.

Security class: Short Put Options (potential obligation to buy)
Shares / value: 1,100
Estimated value: $448,800
Report date: 08 May 2026
Price: $408.00
Ownership: Holdings of BML Investment Partners, L.P.
Underlying class: Common Shares
Underlying amount: 110,000

Form 4 holding 10%+ Owner

Talis Biomedical Corp

Security class: Common Stock
Shares / value: 248,702
Estimated value: $369,074
Report date: 06 Sep 2024
Price: $1.48
Ownership: Holding of BML Investment Partners, L.P.

Form 4 holding 10%+ Owner

Metacrine, Inc.

Security class: Common Stock
Shares / value: 600,000
Estimated value: $282,000
Report date: 19 Dec 2022
Price: $0.4700
Ownership: Direct

Form 4 holding Former 10% owner of RPHM

Reneo Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 102,076
Estimated value: $152,747
Report date: 07 Oct 2024
Price: $1.50
Ownership: Direct

Form 4 holding 10%+ Owner

Satsuma Pharmaceuticals, Inc.

Security class: Common Stock
Shares / value: 150,000
Estimated value: $136,500
Report date: 21 Nov 2022
Price: $0.9100
Ownership: Direct

Form 4 holding Former 10% owner of AVROBIO

Tectonic Therapeutic, Inc.

Security class: Common Stock
Shares / value: 33,333
Estimated value: $43,333
Report date: 20 Jun 2024
Price: $1.30
Ownership: Direct

Form 4 holding 10%+ Owner

ASTROTECH Corp

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 03 Oct 2025
Price: $5.83
Ownership: Direct

Form 4 holding 10%+ Owner

ASTROTECH Corp

Security class: Common Stock
Shares / value: 0
Estimated value: $0
Report date: 03 Oct 2025
Price: $7.13
Ownership: Holdings of BML Investment Partners, L.P

Form 4 holding 10%+ Owner

RETRACTABLE TECHNOLOGIES INC

Security class: Put Option (obligation to buy)
Shares / value: 0
Estimated value
Report date: 28 Nov 2022
Price
Ownership: Holding of BML Investment Partners, L.P.
Underlying class: Common Stock
Underlying amount: 0

Insider Reports Filed by Braden M. Leonard

4 OM

Outset Medical, Inc.

Report period: 15 May 2026
Transactions: 1
Transaction value: $0
Accepted by SEC: 18 May 2026, 09:53
Role: 10%+ Owner
Next action: Open filing details

4 OM

Outset Medical, Inc.

Report period: 08 May 2026
Transactions: 2
Transaction value: $0
Accepted by SEC: 12 May 2026, 16:34
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 27 Apr 2026
Transactions: 1
Transaction value: -$1,359,000
Accepted by SEC: 27 Apr 2026, 19:27
Role: 10%+ Owner
Next action: Open filing details

3/A OM

Outset Medical, Inc.

Report period: 12 Feb 2026
Transactions: 0
Transaction value: $0
Accepted by SEC: 04 Mar 2026, 11:17
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 04 Dec 2025
Transactions: 1
Transaction value: -$2,200,372
Accepted by SEC: 05 Dec 2025, 18:20
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 01 Dec 2025
Transactions: 3
Transaction value: -$2,407,833
Accepted by SEC: 03 Dec 2025, 21:39
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 03 Oct 2025
Transactions: 2
Transaction value: -$1,625,071
Accepted by SEC: 07 Oct 2025, 20:51
Role: 10%+ Owner
Next action: Open filing details

4 ANTX

AN2 Therapeutics, Inc.

Report period: 12 Jun 2025
Transactions: 1
Transaction value: -$218,000
Accepted by SEC: 16 Jun 2025, 15:40
Role: 10%+ Owner
Next action: Open filing details

4 ANTX

AN2 Therapeutics, Inc.

Report period: 28 May 2025
Transactions: 4
Transaction value: -$2,872,477
Accepted by SEC: 30 May 2025, 17:40
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 22 Apr 2025
Transactions: 2
Transaction value: +$1,048,950
Accepted by SEC: 24 Apr 2025, 09:35
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 31 Mar 2025
Transactions: 2
Transaction value: +$147,076
Accepted by SEC: 02 Apr 2025, 18:07
Role: 10%+ Owner
Next action: Open filing details

4/A ADVM

Adverum Biotechnologies, Inc.

Report period: 26 Mar 2025
Transactions: 2
Transaction value: +$188,931
Accepted by SEC: 28 Apr 2025, 15:31
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 26 Mar 2025
Transactions: 2
Transaction value: +$188,931
Accepted by SEC: 28 Apr 2025, 15:24
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 18 Mar 2025
Transactions: 4
Transaction value: +$587,575
Accepted by SEC: 20 Mar 2025, 20:02
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 26 Feb 2025
Transactions: 3
Transaction value: +$1,439,087
Accepted by SEC: 28 Feb 2025, 16:04
Role: 10%+ Owner
Next action: Open filing details

4 OKUR

OnKure Therapeutics, Inc.

Report period: 07 Oct 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 09 Oct 2024, 11:25
Role: Former 10% owner of RPHM
Next action: Open filing details

4 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 24 Sep 2024
Transactions: 2
Transaction value: +$144,738
Accepted by SEC: 26 Sep 2024, 09:33
Role: 10%+ Owner
Next action: Open filing details

4 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 17 Sep 2024
Transactions: 2
Transaction value: +$76,237
Accepted by SEC: 19 Sep 2024, 11:02
Role: 10%+ Owner
Next action: Open filing details

4 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 12 Sep 2024
Transactions: 3
Transaction value: +$484,344
Accepted by SEC: 16 Sep 2024, 16:15
Role: 10%+ Owner
Next action: Open filing details

Talis Biomedical Corp

Report period: 05 Sep 2024
Transactions: 2
Transaction value: +$44,240
Accepted by SEC: 09 Sep 2024, 16:24
Role: 10%+ Owner
Next action: Open filing details

Talis Biomedical Corp

Report period: 03 Sep 2024
Transactions: 1
Transaction value: +$2,000
Accepted by SEC: 05 Sep 2024, 11:57
Role: 10%+ Owner
Next action: Open filing details

Talis Biomedical Corp

Report period: 30 Aug 2024
Transactions: 1
Transaction value: +$642
Accepted by SEC: 04 Sep 2024, 20:19
Role: 10%+ Owner
Next action: Open filing details

Talis Biomedical Corp

Report period: 28 Aug 2024
Transactions: 2
Transaction value: +$56,137
Accepted by SEC: 28 Aug 2024, 16:45
Role: 10%+ Owner
Next action: Open filing details

Talis Biomedical Corp

Report period: 14 Aug 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 14 Aug 2024, 21:13
Role: 10%+ Owner
Next action: Open filing details

4 ANTX

AN2 Therapeutics, Inc.

Report period: 14 Aug 2024
Transactions: 1
Transaction value: +$1,560,000
Accepted by SEC: 14 Aug 2024, 20:24
Role: 10%+ Owner
Next action: Open filing details

4 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 13 Aug 2024
Transactions: 2
Transaction value: +$380,598
Accepted by SEC: 14 Aug 2024, 20:48
Role: 10%+ Owner
Next action: Open filing details

3 ANTX

AN2 Therapeutics, Inc.

Report period: 09 Aug 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 12 Aug 2024, 16:58
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 02 Aug 2024
Transactions: 2
Transaction value: +$472,757
Accepted by SEC: 05 Aug 2024, 15:57
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 30 Jul 2024
Transactions: 1
Transaction value: +$613,470
Accepted by SEC: 31 Jul 2024, 16:19
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 30 Jul 2024
Transactions: 2
Transaction value: +$359,010
Accepted by SEC: 31 Jul 2024, 16:10
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 18 Jul 2024
Transactions: 3
Transaction value: +$201,808
Accepted by SEC: 22 Jul 2024, 16:03
Role: 10%+ Owner
Next action: Open filing details

4 ADVM

Adverum Biotechnologies, Inc.

Report period: 18 Jul 2024
Transactions: 2
Transaction value: +$1,785,662
Accepted by SEC: 18 Jul 2024, 21:16
Role: 10%+ Owner
Next action: Open filing details

3 ADVM

Adverum Biotechnologies, Inc.

Report period: 17 Jul 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 18 Jul 2024, 21:16
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 02 Jul 2024
Transactions: 3
Transaction value: +$405,894
Accepted by SEC: 05 Jul 2024, 14:46
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 27 Jun 2024
Transactions: 4
Transaction value: +$1,742,075
Accepted by SEC: 01 Jul 2024, 13:39
Role: 10%+ Owner
Next action: Open filing details

4 TECX

Tectonic Therapeutic, Inc.

Report period: 20 Jun 2024
Transactions: 2
Transaction value: $0
Accepted by SEC: 25 Jun 2024, 13:42
Role: Former 10% owner of AVROBIO
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 14 Jun 2024
Transactions: 3
Transaction value: +$628,206
Accepted by SEC: 18 Jun 2024, 16:04
Role: 10%+ Owner
Next action: Open filing details

4 ACRS

Aclaris Therapeutics, Inc.

Report period: 11 Jun 2024
Transactions: 4
Transaction value: +$1,781,897
Accepted by SEC: 13 Jun 2024, 18:04
Role: 10%+ Owner
Next action: Open filing details

4 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 14 May 2024
Transactions: 2
Transaction value: +$639,578
Accepted by SEC: 16 May 2024, 08:58
Role: 10%+ Owner
Next action: Open filing details

3 OKUR

Reneo Pharmaceuticals, Inc.

Report period: 14 May 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 16 May 2024, 08:56
Role: 10%+ Owner
Next action: Open filing details

4 TECX

AVROBIO, Inc.

Report period: 13 May 2024
Transactions: 3
Transaction value: +$971,493
Accepted by SEC: 15 May 2024, 11:21
Role: 10%+ Owner
Next action: Open filing details

3/A TECX

AVROBIO, Inc.

Report period: 13 May 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 15 May 2024, 10:51
Role: 10%+ Owner
Next action: Open filing details

3 TECX

AVROBIO, Inc.

Report period: 13 May 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 15 May 2024, 10:31
Role: 10%+ Owner
Next action: Open filing details

Cyteir Therapeutics, Inc.

Report period: 20 Mar 2024
Transactions: 1
Transaction value: +$503,238
Accepted by SEC: 25 Mar 2024, 11:05
Role: 10%+ Owner
Next action: Open filing details

Cyteir Therapeutics, Inc.

Report period: 19 Mar 2024
Transactions: 1
Transaction value: +$342,469
Accepted by SEC: 19 Mar 2024, 16:19
Role: 10%+ Owner
Next action: Open filing details

Cyteir Therapeutics, Inc.

Report period: 15 Mar 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 19 Mar 2024, 16:09
Role: 10%+ Owner
Next action: Open filing details

3 ACRS

Aclaris Therapeutics, Inc.

Report period: 07 Feb 2024
Transactions: 0
Transaction value: $0
Accepted by SEC: 08 Feb 2024, 10:47
Role: 10%+ Owner
Next action: Open filing details

4/A ELVN

IMARA Inc.

Report period: 03 Jan 2023
Transactions: 1
Transaction value: -$5,000,000
Accepted by SEC: 05 Jan 2023, 19:03
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 30 Dec 2022
Transactions: 1
Transaction value: -$80,800
Accepted by SEC: 30 Dec 2022, 16:42
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 29 Dec 2022
Transactions: 1
Transaction value: -$4,800,000
Accepted by SEC: 29 Dec 2022, 16:43
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 28 Dec 2022
Transactions: 2
Transaction value: -$80,800
Accepted by SEC: 29 Dec 2022, 17:18
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 22 Dec 2022
Transactions: 2
Transaction value: -$203,000
Accepted by SEC: 27 Dec 2022, 08:34
Role: 10%+ Owner
Next action: Open filing details

Metacrine, Inc.

Report period: 19 Dec 2022
Transactions: 3
Transaction value: +$107,594
Accepted by SEC: 21 Dec 2022, 16:49
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 02 Dec 2022
Transactions: 1
Transaction value: +$65,599
Accepted by SEC: 02 Dec 2022, 17:38
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 28 Nov 2022
Transactions: 2
Transaction value: -$505,524
Accepted by SEC: 30 Nov 2022, 19:14
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 23 Nov 2022
Transactions: 1
Transaction value: +$24,652
Accepted by SEC: 25 Nov 2022, 10:02
Role: 10%+ Owner
Next action: Open filing details

Satsuma Pharmaceuticals, Inc.

Report period: 21 Nov 2022
Transactions: 1
Transaction value: +$106,740
Accepted by SEC: 23 Nov 2022, 08:38
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 16 Nov 2022
Transactions: 3
Transaction value: +$144,940
Accepted by SEC: 18 Nov 2022, 15:02
Role: 10%+ Owner
Next action: Open filing details

Satsuma Pharmaceuticals, Inc.

Report period: 14 Nov 2022
Transactions: 3
Transaction value: +$4,394,273
Accepted by SEC: 16 Nov 2022, 15:32
Role: 10%+ Owner
Next action: Open filing details

Satsuma Pharmaceuticals, Inc.

Report period: 14 Nov 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 16 Nov 2022, 14:48
Role: 10%+ Owner
Next action: Open filing details

Metacrine, Inc.

Report period: 07 Nov 2022
Transactions: 3
Transaction value: +$68,074
Accepted by SEC: 09 Nov 2022, 17:29
Role: 10%+ Owner
Next action: Open filing details

Metacrine, Inc.

Report period: 27 Oct 2022
Transactions: 2
Transaction value: +$317,328
Accepted by SEC: 31 Oct 2022, 13:47
Role: 10%+ Owner
Next action: Open filing details

4 IRON

Gemini Therapeutics, Inc. /DE

Report period: 26 Oct 2022
Transactions: 1
Transaction value: -$47,025
Accepted by SEC: 27 Oct 2022, 16:23
Role: 10%+ Owner
Next action: Open filing details

Metacrine, Inc.

Report period: 24 Oct 2022
Transactions: 3
Transaction value: +$443,100
Accepted by SEC: 26 Oct 2022, 16:45
Role: 10%+ Owner
Next action: Open filing details

Metacrine, Inc.

Report period: 24 Oct 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 26 Oct 2022, 16:30
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 14 Oct 2022
Transactions: 2
Transaction value: +$81,838
Accepted by SEC: 18 Oct 2022, 14:02
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 23 Sep 2022
Transactions: 3
Transaction value: +$156,608
Accepted by SEC: 27 Sep 2022, 18:12
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 01 Sep 2022
Transactions: 2
Transaction value: +$117,304
Accepted by SEC: 07 Sep 2022, 09:21
Role: 10%+ Owner
Next action: Open filing details

3 ASTC

ASTROTECH Corp

Report period: 24 Aug 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Aug 2022, 11:36
Role: 10%+ Owner
Next action: Open filing details

4 ASTC

ASTROTECH Corp

Report period: 23 Aug 2022
Transactions: 2
Transaction value: +$218,899
Accepted by SEC: 25 Aug 2022, 11:52
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 16 Jun 2022
Transactions: 1
Transaction value: +$92,243
Accepted by SEC: 21 Jun 2022, 09:48
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 03 Jun 2022
Transactions: 2
Transaction value: +$38,027
Accepted by SEC: 07 Jun 2022, 16:12
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 23 May 2022
Transactions: 2
Transaction value: +$252,898
Accepted by SEC: 25 May 2022, 16:10
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 17 May 2022
Transactions: 3
Transaction value: +$534,857
Accepted by SEC: 19 May 2022, 14:48
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 16 May 2022
Transactions: 2
Transaction value: +$50,413
Accepted by SEC: 18 May 2022, 11:00
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 12 May 2022
Transactions: 3
Transaction value: +$553,721
Accepted by SEC: 16 May 2022, 16:02
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 09 May 2022
Transactions: 3
Transaction value: +$281,044
Accepted by SEC: 11 May 2022, 18:28
Role: 10%+ Owner
Next action: Open filing details

4 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 28 Apr 2022
Transactions: 3
Transaction value: +$1,603,219
Accepted by SEC: 02 May 2022, 16:09
Role: 10%+ Owner
Next action: Open filing details

3 RVP

RETRACTABLE TECHNOLOGIES INC

Report period: 28 Apr 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 02 May 2022, 16:03
Role: 10%+ Owner
Next action: Open filing details

4 ELVN

IMARA Inc.

Report period: 21 Apr 2022
Transactions: 2
Transaction value: +$783,840
Accepted by SEC: 25 Apr 2022, 11:05
Role: 10%+ Owner
Next action: Open filing details

3 ELVN

IMARA Inc.

Report period: 21 Apr 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 25 Apr 2022, 10:51
Role: 10%+ Owner
Next action: Open filing details

4 IRON

Gemini Therapeutics, Inc. /DE

Report period: 11 Apr 2022
Transactions: 4
Transaction value: +$1,337,929
Accepted by SEC: 13 Apr 2022, 16:09
Role: 10%+ Owner
Next action: Open filing details

3 IRON

Gemini Therapeutics, Inc. /DE

Report period: 11 Apr 2022
Transactions: 0
Transaction value: $0
Accepted by SEC: 13 Apr 2022, 16:06
Role: 10%+ Owner
Next action: Open filing details

Insider Reports History

Continue from this owner filing history

Reported holdings for Braden M. Leonard

Insider Reports Filed by Braden M. Leonard